Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 January 2012

  • Email
  • Help

News

20/01/2012

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 January 2012

This page lists the opinions adopted at the January 2012 meeting of the Committee for Medicinal Products for Human Use (CHMP) and other important outcomes.

The new format allows users to view the main opinions adopted at the meeting, along with information on referral procedures, in a clear tabular format. Users can click on the links within the page to read individual press releases and more detailed information about the opinions.

The new format replaces the two PDF documents that used to list each meeting's outcome: the CHMP meeting highlights, published on the Friday following the meeting and the CHMP monthly report, published around a week later. The Agency will publish a new page following each month's CHMP meeting.

The Agency is gathering feedback from journalists and other stakeholders. It will make any necessary changes to the format in early 2012.

Positive opinion on new medicine

Name of medicineINNMarketing authorisation applicant
Signifor

Press release: European Medicines Agency recommends approval of new medicine for Cushing’s disease
pasireotideNovartis Europharm Ltd


Negative opinion on new medicine

Name of medicineINNMarketing authorisation applicant
FolotynpralatrexateAllos Therapeutics Ltd


Positive opinions on extensions of therapeutic indications

Name of medicineINNMarketing authorisation holder
RemicadeinfliximabJanssen Biologics B.V.
RotaTeqrotavirus vaccineSanofi Pasteur MSD


Final opinion on safety reviews for non-centrally authorised medicines

Name of medicine
Meprobamate-containing medicines

Press release: European Medicines Agency recommends suspension of marketing authorisations for meprobamate-containing medicines in the European Union


Other CHMP recommendation on safety issues

Name of medicineINNMarketing authorisation holder
Gilenya

Press release: European Medicines Agency starts review of Gilenya (fingolimod)
fingolimodNovartis Europharm Ltd


CHMP recommendation on medication errors

Name of medicineINNMarketing authorisation holder
VelcadebortezomibJanssen-Cilag International N.V.


Other updates

Opinions on consultation procedures on ancillary medicinal substances in medical devices
Opinions on annual re-assessments and renewals
Start of Community reviews
Scientific advice and protocol assistance
Guidelines and concept papers adopted during the January 2011 CHMP meeting
Procedural announcements
Organisational matters

How useful is this page?

Average rating:

 Based on 0 ratings

Add your rating:

See all ratings
0 ratings
0 ratings
0 ratings
0 ratings
0 ratings

Please note that not all documents associated with this page are published at the same time. This page is updated with new documents as soon as they become available. Therefore users are asked to check the page regularly.

Contact point:

Monika Benstetter or
Sabine Haubenreisser
Tel. +44 (0)20 7418 8427
E-mail: press@ema.europa.eu